In late 2022, we noted that the pharmaceutical companies were in a rush to create a new vaccine for babies to protect against the respiratory syncytial virus (RSV). This was a virus that no one had ever heard of before.
At the time, doctors in the US and Great Britain were blaming the sudden deaths of COVID-19-vaccinated children on this RSV thing. So, Big Pharma has been in a big rush to create another jab that they can add to the CDC’s childhood vaccine schedule.
An FDA panel recently approved a clinical safety trial for the AstraZeneca RSV jab, and 12 babied died in the study.
One of the nice things about the COVID jab catastrophe is that it has made many people in the general public aware that there is something seriously off in the entire vaccine industrial complex. If the COVID jabs were able to drop a healthy-as-a-horse person like actor Jamie Foxx or BBC presenter Lisa Shaw, what were they likely to do in a toddler or a young child, many wondered?
Not to mention all the professional and college athletes who were dying from cases of “suddenly.” The Biden administration’s attempted “Shots for Tots” campaign was a complete disaster, as parents quietly withdrew from the whole vaccine scam.
We’re even starting to see the “A”-word creep back into the conversation when it comes to vaccines: autism.
This is especially true now that Twitter is allowing some (but not all) truths to be voiced on the platform again. People are also noticing that sudden infant death syndrome (SIDS) was never a thing until the CDC updated the child vaccine schedule to the 30 or so shots that are on it right now.
AstraZeneca’s new RSV shot is called Nirsevimab. They took their clinical safety trial data to the FDA’s Antimicrobial Drugs Advisory Committee and showed the data to them, asking for clinical approval.
The safety data in the trial showed that 12 babies out of 994 died during the study. That’s .01% of all the babies who got the injection, or one-tenth of one percent. Four of the babies died from cardiac disease. Two perished from gastroenteritis. Two were SIDS deaths. One developed cancer and died from a tumor. One died from pneumonia, and one died from a skull fracture.
The twelfth baby that died should have made major headlines around the globe. AstraZeneca claimed that the baby died from COVID-19. If that were actually true, it would be a historic moment. No healthy child under the age of 18 has died from COVID-19 in any country on earth. It’s never happened before! But we suddenly have our first COVID-19 death in a baby after it receives the Nirsevimab injection in its arm? Not fishy at all!
The FDA panel decided that none of the 12 baby deaths in the study were related to Nirsevimab. AstraZeneca reported to the FDA that this RSV jab is only 48% effective in preventing RSV. So, there’s less than a 50/50 chance that the shot will even prevent your child from getting this illness that is less dangerous than the common cold—but there’s a 1 in 100 chance your baby will die after receiving it.
Don’t ask the doctors at the FDA for pointers before your next trip to Vegas, in other words.
Dr. Meryl Nass is a biological warfare epidemiologist and a member of the Children’s Health Defense network’s scientific advisory committee. She says, “It is reckless in the extreme to inject very young babies with an inadequately tested monoclonal antibody drug to prevent a condition that for most of them will be no more than a cold.”
CHD’s Senior Director of Science and Research Brian Hooker notes that the FDA’s approval of this infant vaccine is likely intended to dupe maternal patients into getting the RSV jab. The shot has already been approved by the FDA for use in pregnant and nursing women, but they are not anxiously lining up to take it for some reason.
AstraZeneca insisted to the FDA panel that the 12 deaths were unrelated to the injections they gave the babies. And the FDA panel said, “Sounds good to us! No need for further study!”
The vote to approve the shots for infants was 21-0. The next step will be to add the shot to the childhood vaccine schedule.